Pioneering the development of engineered IgM antibodies
Cancer Immunotherapy β’ Engineered Therapeutics β’ Engineered IgM Antibodies β’ Infectious Disease β’ Autoimmunity
201 - 500
π° $200M Post-IPO Equity on 2022-03
September 26
201 - 500
Lead global regulatory strategy for immunology programs at IGM Biosciences.
πΊπΈ United States β Remote
π΅ $215k - $280k / year
π° $200M Post-IPO Equity on 2022-03
β° Full Time
π Senior
π Compliance
Join our Facebook group
π Remote Jobs Network